Ovid Therapeutics (NASDAQ:OVID) reported quarterly earnings of $0.06 per share which beat the analyst consensus estimate of $(0.11) by 152.63 percent. This is a 146.15 percent increase over losses of $(0.13) per share from the same period last year. The company reported quarterly sales of $718.000 thousand which beat the analyst consensus estimate of $13.333 thousand by 5.29K percent. This is a 844.74 percent increase over sales of $76.000 thousand the same period last year.